An interventional study of Bismuth quadruple therapy and Triple therapy with PPI + Amoxicillin + Metronidazole in Helicobacter Pylori Infection and Peptic Ulcer, sponsored by Can Tho University of Medicine and Pharmacy. Recruiting at 1 site in Vietnam. Open to participants aged 5 Years to 15 Years. Per ClinicalTrials.gov, last updated 2025-12-02.
Sponsored by Can Tho University of Medicine and Pharmacy · Not applicable, Interventional, and Treatment
The goal of this clinical trial is to learn if including bismuth in the treatment helps heal stomach and duodenal ulcers caused by Helicobacter pylori (H. pylori) in children.
The main questions it aims to answer are:
Researchers will compare two treatment groups to see which works better. Participants will:
193 studies on the registry are indexed under Peptic Ulcer; 31 are open to participants now.
This study's planned enrollment of 80 is below the median of 150 across 142 interventional studies indexed under Peptic Ulcer.
Browse Peptic Ulcer studies →Can Tho University of Medicine and Pharmacy is the lead sponsor of 33 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients in this arm will receive PPI, Amoxicillin, Metronidazole, and Bismuth for 14 days, with doses adjusted according to weight and age.
Drug: Bismuth quadruple therapy
Patients in this arm will receive PPI, Amoxicillin, Metronidazole for 14 days, with doses adjusted according to weight and age.
Drug: Triple therapy with PPI + Amoxicillin + Metronidazole
A 14-day regimen including proton pump inhibitor (PPI; esomeprazole \[Nexium MUPS\]), bismuth subcitrate (or bismuth subsalicylate), amoxicillin, and metronidazole. All drug doses are adjusted according to the participant's age and weight.
A 14-day regimen including proton pump inhibitor (PPI; esomeprazole \[Nexium MUPS\]), amoxicillin, and metronidazole. All drug doses are adjusted according to the participant's age and weight.
Eradication rate of Helicobacter pylori infection between the two treatment regimens
The efficacy of the two regimens will be evaluated by comparing H. pylori eradication rates. Clinical examination and a urea breath test or stool antigen test will be performed after completion of therapy to confirm eradication. Patients will receive a 14-day treatment regimen, followed by an additional 2-4 weeks of proton pump inhibitor (PPI) therapy to promote healing of gastric or duodenal lesions.
Time frame: Two weeks after discontinuation of acid suppression therapy following completion of the eradication regimen.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Can Tho University of Medicine and Pharmacy